Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer

Anticancer Research

Volumn 26, Issue 4 B, 2006, Pages 3187-3190

  Bartsch, Rupert ^a   Woehrer, Stefan ^a   Raderer, Markus ^a   Hejna, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Gastric cancer; Helicobacter pylori; Interleukin 6; MALT lymphoma; Pancreatic cancer

Indexed keywords

INTERLEUKIN 6;

ARTICLE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PANCREAS CANCER; PRIORITY JOURNAL; RANK SUM TEST; STOMACH CANCER; TWO TAILED TEST;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; INTERLEUKIN-6; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; MIDDLE AGED; PANCREATIC NEOPLASMS; STOMACH NEOPLASMS;

EID: 33746736234     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Heinrich PC, Behrmann I, Haan S, Hermann HM, Muller-Newen G and Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20, 2003.
2. Lauta VM: A Review of the cytokine network in multiple myeloma. Cancer 97: 2440-2452, 2003.
3. Trikha M, Corringham R, Klein B and Rossi JF: Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 9: 4653-4665, 2003.
4. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE and Kienast J: Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95: 2630-2636, 2000.
5. Jaffe ES: Common threads of mucosa-associated lymphoid tissue lymphoma pathogenesis: from infection to translocation. J Natl Cancer Inst 96: 571-573, 2004.
6. Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A and Stolte M: Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 53: 34-37, 2004.
7. Crabtree JE, Shallcross TM, Heatly RV and Wyatt JI: Mucosal tumour necrosis factor alpha and interleukin 6 in patients with Helicobacter pylon associated gastritis. Gut 32: 1473-1477, 1991.
8. Gionchetti P, Vaira D, Campieri M, Holton J, Menegatti M, Belluzzi A, Bertinelli E, Ferretti M, Brignola C, Miglioli M et al: Enhanced mucosal interleukin-6 and -8 in Helicobacter pylori-positive dyspeptic patients. Am J Gastroenterol 89: 883-887, 1994.
9. Molosrvov G, Morris A, Rose P, Basu S and Muller G: The effects of selective cytokine inhibitory drugs (CC-10004 and C-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures. Br J Haematol 124: 366-375, 2004.
10. Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, P'eng FK and Chi CW: Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 91: 1417-1422, 1996.
11. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL and Kurzrock R: Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 101: 2727-2736, 2004.
12. Raderer M, Wrba F, Kornek G, Maca T, Koller DY, Weinlaender G, Hejna M and Scheithauer W: Association between Helicobacter pylori infection and pancreatic cancer. Oncology 55: 16-19, 1998.
13. Stolzenberg-Saloman RZ, Blaser MJ, Limburg PJ, Perez-Perez G, Taylor PR, Virtamo J and Albanes D: ATBC Study: Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst 93: 937-941, 2001.
14. Nilson HO, Stenram U, Ihse I and Waldstrom T: Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst 94: 632-633, 2002.
15. Seymour JF and Kurzrock R: Interleukin-6: biologic properties and role in lymphoproliferative disorders. Cancer Treat Res 84: 167-206, 1996.
16. Klein B, Zhang XG, Lu ZY and Bataille R: Interleukin-6 in human multiple myeloma. Blood 85: 863-872, 1995.
17. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T et al: Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74: 1360-1367, 1989.
18. Scala G, Quinto I, Ruocco MR, Arcucci A, Mallardo M, Caretto P, Forni G and Venuta S: Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med 172: 61-68, 1990.
19. Tosato G, Jones K, Breinig MK, McWilliams HP and McKnight JL: Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest 91: 2806-2814, 1993.
20. Seymour JF, Talpaz M, Cabanillas F, Wetzler M and Kurzrock R: Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 13: 575-582, 1995.
21. Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S and and Kurzrock R: Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97: 256-263, 2001.
22. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J and Talpaz M: Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res 53: 2118-2122, 1993.
23. Blay JY, Negrier S, Combaret V, Attali S, Goulot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF et al: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52: 3317-3322, 1992.
24. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY and Simons JW: Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45: 542-549, 1995.
25. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM and Martinez-Maza O: Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 164: 1038-1042, 1991.
26. Chung YC and Chang YF: Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83: 222-226, 2003.
27. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P and Rincon M: Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61: 8851-8858, 2001.
28. Rochman I, Paul WE and Ben-Sasson SZ: IL-6 increases primed cell expansion and survival. J Immunol 174: 4761-4767, 2005.
29. Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K and Graham DY: Relation between cytokines and Helicobacterpylori in gastric cancer. Helicobacter 6: 116-124, 2001.
30. Lin MT, Juan CY, Chang KJ et al: IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis 22: 1947-1953, 2001.
31. Huang SP, Wu MS, Wamg HP, Yang CS, Kuo ML and Lin JT: Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma. J Gastroenterol Hepatol 17: 1165-1169, 2002.
32. Okada S, Okusaka T, Ishii H, Kyogoku A, Yoshimori M, Kajimura N, Yamaguchi K and Kakizoe T: Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn J Clin Oncol 28: 12-15, 1998.
33. Demartini G, Esposti D, Marthyn P, Lapidari A, Fraschini F and Scaglione F: Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFN gamma and IL-10 plasma levels in patients with community acquired pneumonia. J Chemother 16: 82-85, 2004.